| Drug General Information |
| Drug ID |
D0P5PW
|
| Former ID |
DNC004570
|
| Drug Name |
4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C15H14N2
|
| Canonical SMILES |
CC(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
|
| InChI |
1S/C15H14N2/c1-11(15-9-16-10-17-15)13-8-4-6-12-5-2-3-7-14(12)13/h2-11H,1H3,(H,16,17)
|
| InChIKey |
DZSQSLQSMKNVBV-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-1B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
AMPK signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Salivary secretionhsa04020:Calcium signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Endothelin Pathways
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
AMPK SignalingWP58:Monoamine GPCRs
|
|
Platelet Aggregation (Plug Formation)
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Integration of energy metabolism
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Vitamin D Receptor Pathway
|
| References |
| REF 1 | J Med Chem. 1994 Jul 22;37(15):2328-33.A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic receptors. |
|---|
